Meeting Banner
Abstract #0737

Hippocampal Choline Level Predicts Symptomatic Improvement with Agomelatine in Major Depressive Disorder: A 3 Tesla Single Voxel Spectroscopy Study

Najib Allali1, 2, Romain Valabregue2, Malgorzata MarjanskaA3, 4, Pauline Delaveau1, ric Bardinet2, Maritza Jabourian5, Judith LAREDO5, Philippe Fossati1, 6, Stphane Lehricy2, 7

1USR 3246, CNRS, Paris, le-de-France, France; 2Centre de Neuroimagerie de Recherche - CENIR, Institut du Cerveau et de la Moelle pinire - ICM, Paris, le-de-France, France; 3Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, United States; 4Department of Radiology, University of Minnesota, Minneapolis, MN, United States; 5Institut de Recherches Internationales Servier - IRIS, Courbevoie, le-de-France, France; 6Psychiatry, APHP - GH Piti Salptrire, Paris, le-de-France, France; 7UMR-S975 ; Inserm, U975 ; CNRS, UMR 7225, Paris, France, CRICM, Universit Pierre et Marie Curie, Paris, le-de-France, France


In this study, we sought to identify spectroscopic correlates of depressive state and of response to Agomelatine, a new antidepressant with melatonin agonist and 5-HT2C antagonist properties.